The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors.
 
Monica S. Thakar
Honoraria - Miltenyi Biotec
Research Funding - Miltenyi Biotec
 
Meghen Browning
No Relationships to Disclose
 
Parameswaran Hari
Honoraria - Amgen; Celgene; Juno Therapeutics; Novartis; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Pharmacyclics; Sanofi; Takeda
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst)
 
John A. Charlson
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Lilly
 
David A. Margolis
Speakers' Bureau - Jazz Pharmaceuticals
 
Brent Logan
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Enlivex Therapeutics Ltd; Gamida Cell
 
Nathan Schloemer
No Relationships to Disclose
 
Michael E. Kelly
No Relationships to Disclose
 
Amy Newman
No Relationships to Disclose
 
Bryon Johnson
No Relationships to Disclose
 
Carolyn Anne Keever-Taylor
No Relationships to Disclose
 
Subramaniam Malarkannan
No Relationships to Disclose